Welcome to the Horizon 2020 atherosclerosis research program website
2019 ERC Proof of Concept grant for Prof. Esther Lutgens
Under the European Research Council Proof of Concept grant initiative, ERC grantees may now also apply for additional funding to set up, namely, an Intellectual Property Rights (IPR) strategy for the results of their prior ERC project. The funds are granted at the earliest stage of innovation and therefore researchers now have the necessary support
Interesting data from the Copenhagen General Population Study on the effects of smoking on white and red blood cell count.
A Mendelian Randomization Approach in the Copenhagen General Population Study was conducted to assess whether tobacco smoking causally affects white and red blood cells and thrombocyte counts is unknown. Using this approach, the Copenhagen University Hospital, partner in the REPROGRAM project, tested the hypothesis that smoking causes increases in these blood cell indices. They included
The link between hematopoiesis and atherosclerosis
REPROGRAM Principal Investigators working at Amsterdam University Medical Center and Ludwig Maximilians University, Munich published their expert comments on the link between hematopoiesis and atherosclerosis, based on the following article “AIBP-mediated cholesterol efflux instructs hematopoietic stem and progenitor cell fate” in Science. 2019. There is mounting evidence that atherosclerosis is driven not just by dyslipidemia
Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides.
Most DAMPs in inflammatory diseases are TLR2- and TLR4-ligands and according to the current concept, repeated stimuli would result in tolerance. Aims of the study were to verify this assumption, to investigate whether epigenetic effectors are involved and to explore the situation in rheumatoid arthritis (RA).
New scientific article in Cell metabolism 2019.
Patients with hypercholesterolemia have an increased risk for atherosclerotic cardiovascular disease, and despite lipid lowering with statins, an important residual risk remains. We hypothesize that this is due to persistent pro-inflammatory reprogramming of circulating monocytes. Monocyte derived macrophages are key components of atherosclerotic plaques. These cells can build a long-term pro-inflammatory phenotype after brief exposure
Satellite‐congress EAS 2019
Over 50 participants attended the inspiring satellite-congress EAS 2019, co-organized by REPROGRAM, focused on the “Interplay of metabolism, inflammation and vascular biology”. On behalf of REPROGRAM Prof. Niels Riksen (Radboud UMC), Prof. Erik Stroes (Academic Medical Center) and Prof. Matthias Nahrendorf (Harvard Medical School) presented their work and emerging results. This symposium was open to
Joint session (open-end conference) of the REPROGRAM project at the EAS SATELLITE on IMMUNOMETABOLISM (26 May 2019)
Open-end congres REPROGRAM at EAS
On May 26 until May 29 2019 the open-end congres of REPROGRAM will be held at the 87th European Atherosclerosis Society in Maastricht. You can sign in with the following link: https://eas2019.com/the-congress/satellite-symposia/immunometabolism/ Untitled
Grant application MEMORY funded by European Research Area Network on Cardiovascular Diseases (ERA-CVD)
Prof. Niels RIksen (RadboudUmc, Nijmegen) teamed up with dr. Andreas Schlitzer (University of Bonn, Germany) and dr. Hafid Ait-Oufella (St-Antoine Hospital and Inserm , France). They prepared a successful transnational ERA-CVD research application entitled MEMORY. Due to the worldwide adoption of Western lifestyle, the prevalence of obesity increases exponentially. Obesity is an important risk factor for
Governing Council meeting 2019
On January 21 2019, the Governing Council meeting was held at Schiphol Amsterdam airport for the REPROGRAM project. After a warm welcome by Prof. Dr. Erik Stroes (Project Coordinator) the meeting started immediately with presentations of Prof. dr. Niels Riksen (RadboudUMC), Prof. dr. Erik Stroes (AMC), Prof dr.Borge Nordestgaard (Copenhagen University Hospital) and Prof. dr.
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.
